Microbiology Laboratory Testing Practices of Gram-Negative Bloodstream Infections With Difficult-to-Treat Resistant Phenotypes in US Hospitals
Clinical Infectious Diseases · 06.11.2025 · 81 (4) · 710-720
DOI: 10.1093/cid/ciaf165 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 01.04.2025. Verfasst von Shawn H MacVane und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical Affairs, bioMérieux, Hazelwood, Missouri, USA. Hauptthemen laut MEDLINE: Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Gram-Negative Bacteria, Bacteremia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Rapid administration of effective antimicrobial therapy is crucial for managing bloodstream infections (BSIs), especially those caused by pathogens with difficult-to-treat resistance (DTR; ie, resistance to all first-line antimicrobials). The purpose of this study is to describe the epidemiology and time course of microbiological testing in US laboratories for gram-negative BSIs (GN-BSIs).
Methods
A retrospective observational cohort study of adults with GN-BSI between 1 January 2017 and 30 June 2023 was conducted using a large, geographically diverse, hospital-based administrative US database. Antimicrobial susceptibility testing (AST) reporting and time to results of traditional and next-generation antimicrobials (ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, meropenem-vaborbactam, imipenem-relebactam) were evaluated according to the isolates’ resistance phenotype.
Results
A total of 110 322 GN-BSI episodes were included, of which 0.6% exhibited a DTR phenotype. Among all episodes, the average time to results for AST was 73.5 ± 26.7 hours from blood culture collection. The average time to AST results was longer for DTR (92.2 ± 27.8 hours) and carbapenem not-susceptible phenotypes (90.1 ± 28.0 hours) than for nonresistant phenotypes (72.9 ± 26.7 hours). Overall, 2.5% of GN-BSI episodes had AST reported for at least 1 next-generation antimicrobial, increasing from 0.2% in 2017 to 7.7% in 2023. Among patients with isolates showing DTR phenotypes, 30.5% had AST reported for at least 1 next-generation antimicrobial.
Conclusions
Time to AST results for next-generation antimicrobials and antibiotic-resistant organisms is prolonged in US laboratories for blood cultures with gram-negative organisms. Testing frequency and timing of AST reporting for next-generation antimicrobials likely contribute to their clinical utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Medical Affairs, bioMérieux, Hazelwood, Missouri, USA.
- Premier Applied Sciences, Premier, Inc, Charlotte, North Carolina, USA.
- Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Shawn H MacVane, Rena Moon, Romney M Humphries
Zitieren
APA
MacVane, S. H., Moon, R., David, J., Rosenthal, N., & Humphries, R. M. (2025). Microbiology Laboratory Testing Practices of Gram-Negative Bloodstream Infections With Difficult-to-Treat Resistant Phenotypes in US Hospitals. Clinical Infectious Diseases, 81(4), 710-720. https://doi.org/10.1093/cid/ciaf165
Vancouver
MacVane SH, Moon R, David J, Rosenthal N, Humphries RM. Microbiology Laboratory Testing Practices of Gram-Negative Bloodstream Infections With Difficult-to-Treat Resistant Phenotypes in US Hospitals. Clinical Infectious Diseases. 2025;81(4):710-720. doi:10.1093/cid/ciaf165
BibTeX
@article{MacVane2025,
author = {MacVane, Shawn H and Moon, Rena and David, Joy and Rosenthal, Ning and Humphries, Romney M},
title = {Microbiology Laboratory Testing Practices of Gram-Negative Bloodstream Infections With Difficult-to-Treat Resistant Phenotypes in US Hospitals},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {4},
pages = {710--720},
doi = {10.1093/cid/ciaf165}
}
EUVIMED